These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 2378793

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of loxiglumide (CR-1505) on bombesin- and meal-stimulated plasma cholecystokinin in man.
    Jansen JB, Jebbink MC, Douglas BR, Lamers CB.
    Eur J Clin Pharmacol; 1990; 38(4):367-70. PubMed ID: 2344859
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: effects of loxiglumide, a specific cholecystokinin receptor antagonist.
    Baum F, Nauck MA, Ebert R, Cantor P, Hoffmann G, Choudhury AR, Schmidt WE, Creutzfeldt W.
    Digestion; 1992; 53(3-4):189-99. PubMed ID: 1291406
    [Abstract] [Full Text] [Related]

  • 7. Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas.
    Otsuki M, Fujii M, Nakamura T, Okabayashi Y, Tani S, Fujisawa T, Koide M, Baba S.
    Dig Dis Sci; 1989 Jun; 34(6):857-64. PubMed ID: 2470557
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide.
    Lieverse RJ, Jansen JB, Masclee AA, Rovati LC, Lamers CB.
    Gut; 1994 Apr; 35(4):501-5. PubMed ID: 8174988
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide.
    Fried M, Erlacher U, Schwizer W, Löchner C, Koerfer J, Beglinger C, Jansen JB, Lamers CB, Harder F, Bischof-Delaloye A.
    Gastroenterology; 1991 Aug; 101(2):503-11. PubMed ID: 2065926
    [Abstract] [Full Text] [Related]

  • 12. Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loxiglumide.
    Schmidt WE, Creutzfeldt W, Schleser A, Choudhury AR, Nustede R, Höcker M, Nitsche R, Sostmann H, Rovati LC, Fölsch UR.
    Am J Physiol; 1991 Feb; 260(2 Pt 1):G197-206. PubMed ID: 1996640
    [Abstract] [Full Text] [Related]

  • 13. Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans.
    Hildebrand P, Ensinck JW, Ketterer S, Delco F, Mossi S, Bangerter U, Beglinger C.
    J Clin Endocrinol Metab; 1991 May; 72(5):1123-9. PubMed ID: 2022712
    [Abstract] [Full Text] [Related]

  • 14. Effects of somatostatin and loxiglumide on gallbladder motility.
    Lieverse RJ, Jansen JB, Jebbink MC, Masclee AA, Rovati LC, Lamers CB.
    Eur J Clin Pharmacol; 1995 May; 47(6):489-92. PubMed ID: 7768249
    [Abstract] [Full Text] [Related]

  • 15. Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man.
    Hildebrand P, Beglinger C, Gyr K, Jansen JB, Rovati LC, Zuercher M, Lamers CB, Setnikar I, Stalder GA.
    J Clin Invest; 1990 Mar; 85(3):640-6. PubMed ID: 2312719
    [Abstract] [Full Text] [Related]

  • 16. The cholecystokinin receptor antagonist CR1409 increases plasma cholecystokinin in rats.
    Jansen JB, de Jong AJ, Lamers CB.
    Regul Pept; 1989 Feb; 24(2):209-13. PubMed ID: 2922496
    [Abstract] [Full Text] [Related]

  • 17. Effects of CCK receptor blockade on intestinal motor activity in conscious dogs.
    Niederau C, Karaus M.
    Am J Physiol; 1991 Feb; 260(2 Pt 1):G315-24. PubMed ID: 1996649
    [Abstract] [Full Text] [Related]

  • 18. Determination of plasma cholecystokinin (CCK) concentrations by bioassay and radioimmunoassay in man. A critical evaluation.
    Höcker M, Schmidt WE, Creutzfeldt W, Choudhury AR, Nustede R, Schafmayer A, Fölsch UR.
    Regul Pept; 1992 Feb 18; 37(3):255-69. PubMed ID: 1557514
    [Abstract] [Full Text] [Related]

  • 19. Oral administration of loxiglumide (CCK antagonist) inhibits postprandial gallbladder contraction without affecting gastric emptying.
    Corazziari E, Ricci R, Biliotti D, Bontempo I, De Medici A, Pallotta N, Torsoli A.
    Dig Dis Sci; 1990 Jan 18; 35(1):50-4. PubMed ID: 2295294
    [Abstract] [Full Text] [Related]

  • 20. Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.
    Konturek JW.
    J Physiol Pharmacol; 1994 Dec 18; 45(4 Suppl 1):3-66. PubMed ID: 7787215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.